CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

ofatumumab

Last Updated: December 3, 2020
Result type: Reports
Project Number: SR0657-0000
Product Line: Reimbursement Review

Generic Name: ofatumumab

Brand Name: TBC

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Multiple Sclerosis, relapsing

Indications: For the treatment of Relapsing Multiple Sclerosis (RMS).

Manufacturer Requested Reimbursement Criteria1: For the treatment of Relapsing Multiple Sclerosis (RMS)

Submission Type: Initial

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 27, 2020
Call for patient input closedSeptember 16, 2020
Clarification:

- Patient input submission received from MS Society of Canada

Submission receivedAugust 25, 2020
Submission acceptedSeptember 09, 2020
Review initiatedSeptember 10, 2020
Draft CADTH review report(s) provided to sponsor for commentNovember 24, 2020
Deadline for sponsors commentsDecember 03, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issued to sponsorFebruary 01, 2021
To
February 03, 2021